This chemical is primarily utilized in the field of targeted protein degradation, specifically for research and development of PROTAC (Proteolysis Targeting Chimeras) molecules. It serves as a key component in designing compounds that selectively degrade BRD4, a protein implicated in various cancers and inflammatory diseases. By binding to BRD4, it enables the recruitment of E3 ubiquitin ligase, leading to the ubiquitination and subsequent degradation of the target protein via the proteasome pathway. This approach is being explored for its potential in developing novel therapeutics for conditions such as leukemia, lymphoma, and other BRD4-dependent disorders. Its application is largely confined to preclinical studies aimed at understanding and optimizing PROTAC technology for targeted cancer therapy.